Product Information
Registration Status: ActiveSIN06396P
WILISAN RINGWORM COMPOUND LOTION is approved to be sold in Singapore with effective from 1991-04-07. It is marketed by CHONG PARK MEDICAL HALL (SINGAPORE) PTE LTD, with the registration number of SIN06396P.
This product contains Resorcinol 2% w/v, and Salicylic Acid 5% w/v in the form of LOTION. It is approved for TOPICAL use.
This product is manufactured by CHONG PARK MEDICAL HALL SDN BHD in MALAYSIA.
It is an Over-the-counter Medicine that can be freely obtained from any retailer
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
Indication
For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.
Mechanism of Action
Fluorescein sodium is used extensively as a diagnostic tool in the field of ophthalmology. Fluorescein is a fluorescent compound or fluorophore having a maximum absorbance of 494 m and an emission maximum of 521 nm. The yellowish-green fluorescence of the compound can be used to demarcate the vascular area under observation, distinguishing it from adjacent areas. It is applied topically in the form of a drop or it can be injected intravenously to produce a fluorescein angiogram. Topical fluorescein is a useful tool in the diagnosis of corneal abrasions, corneal ulcers, herpetic corneal infections, and dry eye. Fluorescein angiography is used to diagnose and categorize macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors.
Pharmacokinetics
- Absorption
- Rapidly distributed
- Distribution
- * 0.5 L/kg
- Metabolism
- Elimination
Clearance
* renal cl=1.75 mL/min/kg [After IV administration] * hepatic cl=1.50 mL/min/kg [After IV administration]
Active Ingredient/Synonyms
3,6-fluorandiol | 3',6'-dihydroxyfluoran | 9-(o-carboxyphenyl)-6-hydroxy-3-isoxanthenone | 9-(o-carboxyphenyl)-6-hydroxy-3H-xanthen-3-one | C.I. Solvent Yellow 94 | D and C Yellow No. 7 | D&C Yellow No. 7 | Fluoresceine | Fluoreszein | Japan Yellow 201 | Resorcinolphthalein | Solvent Yellow 94 | Yellow fluorescein | Fluorescein |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
A compound obtained from the bark of the white willow and wintergreen leaves, and also prepared synthetically. It has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.
Indication
Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.
Mechanism of Action
Salicylic acid directly and irreversibly inhibits the activity of both types of cyclo-oxygenases (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. Salicylate may competitively inhibit prostaglandin formation. Salicylate's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. It works by causing the cells of the epidermis to slough off more readily, preventing pores from clogging up, and allowing room for new cell growth. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid inhibits the oxidation of uridine-5-diphosphoglucose (UDPG) competitively with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to the phenolic acceptor. The wound-healing retardation action of salicylates is probably due mainly to its inhibitory action on mucopolysaccharide synthesis.
Toxicity
Oral rat LD50: 891 mg/kg. Inhalation rat LC50: > 900 mg/m3/1hr. Irritation: skin rabbit: 500 mg/24H mild. Eye rabbit: 100 mg severe. Investigated a mutagen and reproductive effector.
Active Ingredient/Synonyms
2-Carboxyphenol | 2-Hydroxybenzoic acid | O-carboxyphenol | O-hydroxybenzoic acid | Salicylic acid |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.